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Summary Kodamaea (Pichia) ohmeri was formerly considered a contaminant, but is now
known to be a significant human pathogen that has been shown to cause fungemia, endocarditis,
funguria, and peritonitis in immunocompromised patients. We report a case of fungemia caused by
K. ohmeri in a 71-year-old man with cellulitis. The patient was sent to the emergency room due to
leg edema, fever, and change of consciousness. During hospitalization, a series of examinations
including blood cultures were performed. On hospital day 8, blood culture yielded a yeast colony.
Fluconazole was given empirically, but had no effect. The pathogen was identified as K. ohmeri by
Vitek YBC card, API 20C, sequencing of the 18S rRNA gene, and the D1/D2 domains of the 26S rRNA
gene and the internally transcribed spacer (ITS) regions. Antifungal susceptibility testing was
performed with the ATB-Fungus system, and a high minimum inhibitory concentration (level up to
64 mg/l) for fluconazole was found. Fluconazole was replaced with amphotericin B deoxylate, and
the fever and cellulitis inflammation gradually subsided. The patient was discharged in a stable
condition. This is the first case of K. ohmeri fungemia in Taiwan.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +886 0966 208339;
fax: +886 4 2203 1029.
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Kodamaea (Pichia) ohmeri is an unusual pathogen of mycosis.
In the last 20 years, only 19 cases have been described in the
literature.1—13All reported cases had significant predisposingPublished by Elsevier Ltd. All rights reserved.
Figure 1 Colony morphology of Kodamaea ohmeri on CHRO-
Magar showing a pink to blue transition.
Figure 2 Pseudohyphae (long arrow) and blastoconidia (short
arrow) of Kodamaea ohmeri on corn meal agar under light
microscope.
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catheters, etc. However, the association between cellulitis of
tinea pedis and fluconazole-resistant K. ohmeri has not been
described.We present in this report the first case in Taiwan of
fungemia caused by fluconazole-resistant K. ohmeri in a 71-
year-old man with persistent tinea pedis cellulitis of the
bilateral lower extremities.
Case report
The patient
A 71-year-old Taiwanese man with type 2 diabetes mellitus
(DM) and tinea pedis of the bilateral lower extremities for
several months was sent to our emergency room in March
2006 due to a sudden episode of disturbance of conscious-
ness, fever, and bilateral lower leg swelling. On admission,
he was pyrexial with a temperature of 39.9 8C, a Glasgow
coma score of 11 (E3M4V4), pulse rate of 84/min, respiratory
rate of 24/min, and blood pressure of 130/80 mmHg. No
neurological deficits were detected. Examination of the
extremities revealed bilateral leg edema (grade I—II), des-
quamation, and erythematous swelling. Hematological and
biochemical investigations revealed a white cell count of
7  109/l (74.9% neutrophils, 19.3% lymphocytes, 4.9%
monocytes), platelet count of 194  109/l, glucose of 14.4
mmol/l, and C-reactive protein (CRP) of 8 mg/l. Two sets of
blood samples were obtained from a peripheral vein for
culture. Urine analysis was normal except for proteinuria
and glucosuria. Under the impression of cellulitis-related
sepsis, the patient was treated empirically with oxacillin
(2 g every 4 hours IV) for 12 days, but remained febrile
(37.6—38.5 8C). On hospital day 7, the blood culture from
hospital day 1 grew yeast, and fluconazole (400 mg daily
oral) was prescribed. Blood cultures were repeated on hos-
pital day 10 and hospital day 14. On hospital day 12, oxacillin
was replaced with imipenem—cilastatin (500 g every 8 hours
IV) because of persistent fever. On hospital day 13, the yeast
was identified as K. ohmeri with a high minimum inhibitory
concentration (MIC; 64 mg/l) for fluconazole. Therefore,
fluconazole was replaced with amphotericin B (25 mg daily
IV). Subsequent blood cultures were negative, and the
patient was discharged in a stable condition on hospital
day 20.
The organism
Twenty-four hours after subculture on Sabouraud dextrose
agar, white rough colonies of yeast were observed. No germ
tube formation was detected. On CHROMagar (Beckton Dick-
inson, Paris, France), the yeast exhibited membranous colo-
nies that changed color from pink to blue within 48 hours
(Figure 1). On corn meal agar (Beckton Dickinson, Paris,
France) containing Tween-80, pseudohyphae and blastoconi-
dia were seen 24 hours later (Figure 2). The organism failed
to grow on Mycosel agar, which has been shown to be useful
for the recovery of dermatophytes.14 Biochemical reactions
on Vitek YBC and API 20C AUX (bioMe´rieux, France) showed a
99% probability of K. ohmeri, with bionumbers of 554647011
and 6156376. The yeast was identified as K. ohmeri based on
the results of biochemical tests and sequencing analysis ofthe 18S rDNA. The 18S rDNA genewas amplified by a PCR using
the highly conserved yeast primers 89F (50-GCGAATGGCTCGT-
TAAATCAG-30) and 1758R (50-ACTTTTAGTTCCTCTAAATGACC-
30). Nucleotide sequencing was performed with primers 559F
(50-CTGGTGCCAGCAGCCGCG-30), 797F (50-GCATGGAATAATA-
GAATAGG-30), and 816R (50-CCTATTCTATTATTCCATGC-30). The
18S rDNA sequence of the isolates was found to be identical to
that of K. ohmeri (GenBank accession No. EF374094). The
large subunit ribosomal DNA D1/D2 domain and its internally
transcribed spacer (ITS) were also amplified and sequenced
using the following primers: NL-1: 50P-GCATATCAATAAGCG-
GAGGAAAAG-30P, NL-4m: 50P-GGTCCGTGTTTCAAGACG-30P;
fungi ITS1: TCCGTAGGTGAACCTGCGG, fungi ITS4: TCCTCCG-
CTTATTGATATGC. The results of these additional nucleotide
sequencing reactions confirmed that the organism was
K. ohmeri.
Antifungal susceptibility testing was performed with the
ATB-Fungus system (bioMe´rieux, France), and the MICs of the
antifungal agents for this yeast were as follows: amphotericin
B <0.5 mg/l; fluconazole 64 mg/l; flucytosine <0.5 mg/l;
itraconazole 0.5 mg/l. According to the Clinical and Labora-
tory Standards Institute (CLSI)15 recommended breakpoints
(in mg/l) for Candida spp, the isolated K. ohmeri was con-
sidered resistant to fluconazole, sensitive to flucytosine and
amphotericin B, and intermediate to itraconazole.
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Kodamaea ohmeri, previously known as Pichia ohmeri or
Yamadazyma ohmeri, is a yeast within the family of Sacchar-
omycetaceae.16 K. ohmeri is the teleomorphic form of Can-
dida guilliermondii and is widely used for the fermentation of
fruit, pickles, and rinds.17 The first clinical isolate was from a
pleural effusion and was considered a contaminant.1 Twenty
cases of K. ohmeri infection, including the one in this study,
have been reported (Table 1). Among them, 17 were funge-
mia, and the remaining three were peritonitis (patient 3),
funguria (patient 6), and polymicrobial wound infection
(patient 10). Our patient developed K. ohmeri fungemia
and was the second reported case with cellulitis. These 20
cases included 16 males and four females, aged 0—84 years
with a median age of 47.5 years. Two cases were of pre-
mature newborns (patients 13 and 19) with neonatal instead
of maternal infections, suggesting that premature birth is a
risk factor. The symptoms of K. ohmeri infection varied, and
included fever, acute pain, andmalaise. All the patients were
immunocompromised, except patient 5 who was a 76-year-
old man without pre-existing immunosuppressed status.
Seventy percent (14 cases, patients 1—3, 6—9, 12, and
14—19) of K. ohmeri cases were catheter-related, suggesting
that breakdown of the skin mucosal barrier is a significant risk
factor for K. ohmeri infection. Our patient had significant
cellulitis of the lower extremities, which could have con-
tributed to this episode of fungemia.
Although our patient had only one set of blood cultures
positive for K. ohmeri, we considered the isolated yeast
the true pathogen for the following two reasons. First,
empiric treatment with oxacillin and then fluconazole
were both ineffective, and fever and inflammation
improved only after switching antibiotic regimen to
amphotericin B. Second, no secondary pathogen was iden-
tified from all blood cultures, and no other infectious agent
was discovered. Further, there was no evidence of other
underlying diseases, such as endocarditis, phlebitis, urin-
ary tract infection, or respiratory infection. These findings
indicate that the patient’s sepsis was due solely to K.
ohmeri fungemia.
The current treatment strategy for K. ohmeri infections
includes the removal of medical devices (e.g., Foley cathe-
ter, central venous catheter, and pacemaker) and the use
of effective antifungal agents. Previous reports have sug-
gested that amphotericin B and fluconazole are effective in
the treatment of K. ohmeri fungemia.6,8,10 However, there
is no definite indication as to which drug is superior to the
others.9 Combined treatment with antifungal agents and
surgical removal of an implanted device or catheter in
previous cases (patients 3—5, 9, 14) has contributed to
better outcomes than medical therapy alone. However,
40% (eight patients) of all cases died despite antifungal
therapy. Therefore, K. ohmeri infection in immunocom-
promised patients should be considered a potentially
critical condition.
Fungal infection in immunocompromised patients is com-
mon and may progress to fatal disease. There are many
underlying conditions that may predispose patients to inva-
sive saprophytic fungi,1—3,6 including diabetes, malignancy,
premature birth, and the use of immunosuppressive agents.
Another adverse outcome is associated with the developmentof drug resistance. As described in the first case report,1 K.
ohmeri was resistant to fluconazole, and escalating doses of
amphotericin B were used to treat the infection. Our anti-
fungal susceptibility results also disclose this drug resistance
(Table 1). When the MICs for the isolates from different
patients were compared, all isolates were found to be sus-
ceptible to amphotericin B. Of the 13 available antifungal
susceptibility results, seven isolates were sensitive to fluco-
nazole (MIC 2.0—8.0 mg/l) and five were intermediate (MIC
16.0—32.0 mg/l). The other isolates were documented as
intermediate to fluconazole (MIC 32 mg/l). Our isolate
was the only one definitely resistant to fluconazole with a
MIC of 64 mg/l.
Two cases in the pediatric intensive care unit10 were the
first outbreak of K. ohmeri infection. Both patients were
infected with fluconazole-susceptible K. ohmeri (MIC
8.0 mg/l). One survived after amphotericin B treatment,
but the other died despite fluconazole treatment. In our
patient, both cellulitis and the febrile state resolved gradu-
ally after the antifungal agent was switched from fluconazole
to amphotericin B.
Early administration of amphotericin B was found to have
a better survival rate (80%, 4/5) than empiric use of fluco-
nazole (50%, 6/12). Up to now, all K. ohmeri isolates have
been found to be susceptible to amphotericin B. Since
amphotericin B is nephrotoxic in a dose-dependent manner,
the use of a lower dose is preferred. However, in severely
immunosuppressed patients with a systemic mycosis, a less
favorable clinical outcome may result from the use of low
doses of amphotericin B.18,19
Since the complicated medical status in immunocompro-
mised patients is strongly correlated with a high mortality of
K. ohmeri infection, knowledge of the fluconazole-resistance
property of K. ohmeri is crucial to ensure proper selection of
antimicrobial agents for empiric therapy. Fluconazole resis-
tance of K. ohmeri indicates that this drug is less useful as an
empiric agent. We suggest that itraconazole instead of flu-
conazole be the first choice of treatment for K. ohmeri
infections. If itraconazole or another azole agent is ineffec-
tive, amphotericin B should then be used. A cumulative dose
of 700 mg of amphotericin B (1 mg/kg per day) over a 14-day
period10 wound be sufficient to eradicate this organism and
prevent relapse.
Because K. ohmeri has a low susceptibility to fluconazole
and may cause nosocomial infections, rapid and accurate
identification is essential. Further studies are needed to
develop new methods for the early identification of fungal
infections. Our K. ohmeri isolate exhibited a characteristic
color change from pink to blue over a 48-h period on CHRO-
Magar Candida medium. This could be a preliminary identi-
fication of K. ohmeri. The sequence analysis of the 18S rRNA
gene, the D1/D2 domains of the 26S rRNA gene and the ITS
regions are useful for a definitive species identification of K.
ohmeri isolates.
In conclusion, the evidence indicates that K. ohmeri
should be added to the list of potential yeast pathogens that
can cause systemic infections in humans of all ages, parti-
cularly in immunocompromised patients. Because increasing
numbers of cases of K. ohmeri fungemia have been reported
with high mortality, early diagnosis and appropriate treat-
ment with removal of any implanted devices are vital in the
management of this potentially fatal infection.
Table 1 Summaries of 20 patients with Kodamaea ohmeri infections reported in the world literature
Case Reference
(year)
Country Age, years/
sex
Pre-existing conditions
or risk factors
Source of K.
ohmeri
MIC (mg/l) Antifungal
treatment
Outcome
AmBa FCZ ICZ
1 1 (1998) USA 48/F DM, kidney transplant,
use of corticoids, CVC
Blood ND ND ND FCZ, then AmB Died
2 2 (2000) The
Netherlands
71/M DM, pacemaker, laparotomy,
endocarditis, numerous
vascular catheters
during hospitalization
Blood ND ND ND AmB Died
3 3 (2000) Hong Kong 64/M Peritoneal dialysis Peritoneal fluid ND ND ND Catheter removal,
FCZ then AmB
Recovered
4 4 (2002) Portugal 42/M Intravenous heroin use, HCV Blood + embolus ND ND ND Valve replacement,
AmB and flucytosine
Recovered
5 5 (2002) USA 76/M Bioprosthetic valve
replacement,
pacemaker implant
Blood + vegetation S (0.25) S (4.0) S (0.03) Valve replacement and
pacemaker removal,
FCZ, then AmB
Recovered
6 6 (2002) Spain 73/M Hodgkin lymphoma, use of
corticoids, Foley catheter
Urine ND ND ND FCZ Recovered
7 7 (2002) Japan 84/M SCC of right maxillary sinus,
CVC for alimentation
Blood + CVC tip ND ND ND CVC removal, FCZ,
then AmB
Died
8 8 (2003) Korea 59/M VP shunt infection,
long hospital stay
Skin lesion of
phlebitis + blood
S (0.5) S (4.0) I (0.5) AmB Recovered
9 9 (2004) Korea 14/M ALL, neutropenia Blood + PAC tip S (0.5) I (32.0) I (0.25) PAC removal, FCZ Recovered
10 9 (2004) Korea 75/M Hip tumor wound with
surgical resection
Wound S (1.0) I (32.0) S (0.008) Drainage, FCZ Died
11 10 (2005) Turkey 8 months/M Encephalitis Blood S (0.008) S (8.0) ND FCZ Died
12 10 (2005) Turkey 10/M B-cell ALL, neutropenia, CVC Blood S (0.008) S (8.0) ND AmB Recovered
13 11 (2006) USA neonate/F Premature, 680 g weight,
necrotizing enterocolitis
Blood S (0.064) I (32.0) ND FCZ, AmB then
liposomal AmB
Recovered
14 12 (2006) Brazil 58/M CML accelerated phase,
CVC, chemotherapy
Blood/catheter tip S (0.5) S (4.0) ND CVC removal, AmB Recovered
15 13 (2007) Korea 11/M Burkitt’s lymphoma,
neutropenia, CVC
Blood S (0.25) I (32.0) I (0.5) CVC removal, FCZ Died
16 13 (2007) Korea 41/M Alcoholic ketoacidosis,
tuberculosis, CVC
Blood S (0.25) I (16.0) I (0.25) CVC removal alone Recovered
17 13 (2007) Korea 47/M DM, chronic renal failure, CVC Blood S (0.25) S (4.0) S (0.125) CVC removal, FCZ, then AmB Died
18 13 (2007) Korea 4/F Tetralogy of Fallot, CVC Blood S (0.25) I (16.0) S (0.125) FCZ and AmB Died
19 13 (2007) Korea neonate/F Premature with very low
birth weight, CVC
Blood S (0.5) S (2.0) S (0.125) CVC removal alone Recovered
20 Present case Taiwan 71/M DM, cellulitis (tinea pedis) Blood S (0.5) R (64.0) I (0.5) FCZ, then AmB Recovered
MIC, minimum inhibitory concentration; DM, diabetes mellitus; CVC, central venous catheter; SCC, squamous cell carcinoma; VP shunt, ventriculoperitoneal shunt; ALL, acute lymphoblastic leukemia;
CML, chronicmyelogenous leukemia;HCV,hepatitis C virus; PAC, port-a-cath; AmB,amphotericinB; FCZ,fluconazole; ICZ, itraconazole; S, susceptible; I, intermediate; R, resistant;ND,nodata reported.
a For AmB, a MIC of 2 mg/l is considered resistance (CLSI, 2005).
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